Funding
Karolinska Institutet
the Swedish Foundation for Strategic Research
the Swedish Research Council
the Swedish Cancer Society
the Swedish Childhood Cancer Foundation
the Åke Wiberg Foundation
the Magnus Bergwall Foundation
the Royal Swedish Academy of Sciences
the Syskonen Svensson Foundation
the Swedish National Board of Health and Welfare
AIRC
UICC International Cancer Technology Transfer Fellowship
Karolinska Intitutet
Higher Education Commission Pakistan
FIRC Post Doc Fellowship
Karolinska Research Internship
ARTICLE ABSTRACT
Natural killer (NK) cells are most efficient if their targets do not express self MHC class I, because NK cells carry inhibitory receptors that interfere with activating their cytotoxic pathway. Clinicians have taken advantage of this by adoptively transferring haploidentical NK cells into patients to mediate an effective graft-versus-leukemia response. With a similar rationale, antibody blockade of MHC class I–specific inhibitory NK cell receptors is currently being tested in clinical trials. Both approaches are challenged by the emerging concept that NK cells may constantly adapt or “tune” their responsiveness according to the amount of self MHC class I that they sense on surrounding cells. Hence, these therapeutic attempts would initially result in increased killing of tumor cells, but a parallel adaptation process might ultimately lead to impaired antitumor efficacy. We have investigated this question in two mouse models: inhibitory receptor blockade in vivo and adoptive transfer to MHC class I–disparate hosts. We show that changed self-perception via inhibitory receptors in mature NK cells reprograms the reactivity such that tolerance to healthy cells is always preserved. However, reactivity against cancer cells lacking critical MHC class I molecules (missing self-reactivity) still remains or may even be increased. This dissociation between activity against healthy cells and tumor cells may provide an answer as to why NK cells mediate graft-versus-leukemia effects without causing graft-versus-host disease and may also be utilized to improve immunotherapy. Cancer Immunol Res; 4(2); 113–23. ©2015 AACR.
